SOLTF (SOLTF) Stock Price & Analysis
SOLTF (SOLTF) fell 12.86% to USD 6.1 as of June 10, 2026 at 02:24 UTC, according to Nexqual real-time market data.
SOLTF last closed at USD 7; the session ranged USD 6.1–6.1 on volume of 1,050 shares. Market capitalization is $559.56M, with a 52-week range of USD 4.9–7.31 (PNK). Source: Nexqual, June 10, 2026 at 02:24 UTC.
Key Statistics (as of June 10, 2026 at 02:24 UTC)
| Price | USD 6.1 |
|---|---|
| Change | ▼ 12.86% (down) |
| Previous Close | USD 7 |
| Open | USD 6.1 |
| Day Range | USD 6.1 – 6.1 |
| 52-Week Range | USD 4.9 – 7.31 |
| Volume | 1,050 shares |
| Market Cap | $559.56M |
| Exchange | PNK |
Technical Analysis (SOLTF)
Nexqual's technical model rates SOLTF "NEUTRAL" based on 3 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:24 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 29.25 (oversold) |
| vs SMA50 | Below (USD 6.35) |
| MACD | 0 (positive) |
Analyst Ratings (SOLTF)
Wall Street analysts rate SOLTF "None", per Nexqual as of June 10, 2026 at 02:24 UTC.
| Consensus Rating | None |
|---|
Earnings (SOLTF)
| Next Earnings Date | 2026-05-01 |
|---|
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financials & Fundamentals (SOLTF)
| Total Revenue | $34.23B |
|---|---|
| Revenue Growth (YoY) | +69.40% |
| Gross Margin | +77.50% |
| Operating Margin | +28.83% |
| Profit Margin | -29.15% |
| ROE | -15.26% |
| Debt / Equity | 87.66 |
| Current Ratio | 2.61 |
| Total Cash | $11.60B |
| Total Debt | $55.83B |
| Free Cash Flow | $-13.82B |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financial Health Score (SOLTF)
Nexqual rates SOLTF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:24 UTC.
| Growth | Mixed — Revenue +2.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 78%, operating 29% |
| Balance Sheet | Mixed — $11.6B cash vs $55.8B debt |
| Cash Flow | Weak — FCF negative: -$13.8B, burning cash |
| Efficiency | Critical — ROE -15%, ROA -1.4% |
Ownership (SOLTF)
| Insider Ownership | +18.07% |
|---|---|
| Institutional Ownership | +34.83% |
| Shares Outstanding | 91.73M |
| Float | 68.93M |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Leadership (SOLTF)
SOLTF is led by Christopher Cargill (age 41), Representative Executive Officer, President, CEO & Chairman, per Nexqual as of June 10, 2026 at 02:24 UTC.
| Representative Executive Officer, President, CEO & Chairman | Christopher Cargill (age 41) |
|---|---|
| Executive Officer & CFO | Hironoshin Nomura (age 42) |
| President of Nxera Pharma Japan & COO | Toshihiro Maeda (age 46) |
| Chief Scientific Officer, President of Nxera Pharma UK & Director | Patrik Foerch |
| Associate Director & Head of Biophysics | Stacey Southall |
Major Backers & Investors (SOLTF)
Notable institutional backers of SOLTF include DFA INVESTMENT TRUST CO-The Japanese Small Company Series, according to Nexqual as of June 10, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Japanese Small Company Series | 0.36% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.52% |
| BlackRock | 1.49% |
| Dimensional Fund Advisors | 0.34% |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TLPPF | Telix Pharmaceutical Ltd. | USD 9.5 | ▲ 0% |
| IDRSF | IDORSIA LTD | USD 5.75 | ▲ 0% |
| ZLDPF | Zealand Pharma A/S | USD 42.03 | ▼ 15.52% |
| IVBXF | Innovent Biologics Inc. | USD 10.76 | ▲ 6.6% |
| NURPF | Neuren Pharmaceuticals Ltd. | USD 9.25 | ▲ 4.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:24 UTC. This page is informational and not investment advice.